SEC Form 4 · accession 0001104659-17-032410
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth B Lee Jr.
Director
Period of report
May 11, 2017
Accepted (ET)
May 12, 2017 · 9:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | May 11, 2017 | A | 7,500 | $0.00 | A | 102,952 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Option (right to buy)F3 | $1.56 | May 11, 2017 | A | 15,000 | A | — | May 11, 2027 | Common Stock, without par value | 15,000 | 15,000 | D |
Explanation of responses
- F1Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date.
- F2Includes 95,452 shares of Common Stock and 7,500 Restricted Stock Units.
- F3The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date.